Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
50567-35-6
Molecular formula
C13H17N3O4S
Molecular weight
311.36 g/mol
Drug class
Pyrazolone analgesic and antipyreticnon-opioid pain reliever with spasmolytic activity
Mechanism of action
The exact mechanism is not fully established. Metamizole and its metabolites produce analgesic, antipyretic and spasmolytic effects; proposed actions include central and peripheral modulation of prostaglandin pathways and other pain-signalling mechanisms.
Indications / reported uses
Acute severe pain following trauma or surgery
Painful colic and other severe pain when alternative measures are inadequate or contraindicated
High fever unresponsive to other measures, only in jurisdictions and formulations where authorised; use is restricted in some countries because of agranulocytosis risk
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Metamizole Environmental Risk Assessment (ERA) (the Metamizole ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.